MOD GRF 1-29 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-10 and is reviewed periodically as new material appears.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
N-Acetylaspartylglutamic acid (N-acetylaspartylglutamate or NAAG) is a peptide neurotransmitter and the third-most-prevalent neurotransmitter in the mammalian nervous system. NAAG consists of N-acetylaspartic acid (NAA) and glutamic acid coupled via a peptide bond. NAAG was discovered as a nervous system-specific peptide in 1965 by Curatolo and colleagues but initially disregarded as a neurotransmitter and not extensively studied. However it meets the criteria for a neurotransmitter, including being concentrated in neurons, packed in synaptic vesicles, released in a calcium-dependent manner, and hydrolyzed in the synaptic space by enzymatic activity. NAAG activates a specific receptor, the metabotropic glutamate receptor type 3. It is synthesized enzymatically from its two precursors and catabolized by NAAG peptidases in the synapse. The inhibition of the latter enzymes has potentially important therapeutic effects in animal models of several neurologic conditions and disorders. Under the INN spaglumic acid, NAAG is used as an antiallergic medication in eye drops and nasal preparations.
The ability of the medium to swell in liquid is based on the cross-linking of these substances, the pH and the ion concentrations of the buffers used. Incorporation of high temperature and pressure allows a significant increase in the efficiency of ion chromatography, along with a decrease in time. Temperature has an influence of selectivity due to its effects on retention properties. The retention factor (k = (tRg − tMg)/(tMg − text)) increases with temperature for small ions, and the opposite trend is observed for larger ions. Despite ion selectivity in different mediums, further research is being done to perform ion exchange chromatography through the range of 40–175 °C. An appropriate solvent can be chosen based on observations of how column particles behave in a solvent. Using an optical microscope, one can easily distinguish a desirable dispersed state of slurry from aggregated particles.
Pepino, a refreshing and thirst-quenching fruit, was eaten by common folk, but scorned by "pampered folk" and was considered difficult to digest. Another fruit that was available to the Incas was the passion fruit (Passiflora spp.) which was actually named so by the Spanish conquistadors and explorers due to the claim that the flowers of the plant contained the symbols of the passion of Christ. The fruit itself is like a pomegranate as they both have a mass of seeds covered by juicy flesh. A fruit that was described as an interesting snack available in the Andes during the time of the Inca Empire was the paqay (Inga feuilleei), or the guaba, which was known for its sweet, spongey substance that covers its seeds. A lesser valued fruit within Inca cuisine was the lúcuma (Lucuma bifera) which was difficult to consume and had little flavor. Opposite to the lucuma in popularity, due to their tender texture and the sweet juice they produce, were the almonds within Caryocar amygdaliferum of the Chachapoyas. They were luxury goods for many generations as many have been found within early tombs of the region.
In March 2017, Lilly acquired CoLucid Pharmaceuticals for $960 million, obtaining the late clinical-stage migraine therapy candidate lasmiditan. In August 2017, Lilly and Shionogi jointly licensed their product varespladib to Ophirex for Ophirex's novel snakebite treatment program. In May 2018, Lilly acquired Armo Biosciences for $1.6 billion, obtaining the white blood cell-boosting cancer treatment candidate pegilodecakin. Days later, the company announced it would acquire Aurora kinase A inhibitor developer AurKa Pharma, and control over the lead compound, AK-01, for up to $575 million. In January 2019, Lilly announced it would acquire Loxo Oncology for $235 per share, valuing the business at around $8 billion, which significantly expanded the business's oncology offerings. The deal gave Lilly Loxo's oral TRK inhibitor, Vitrakvi (Larotrectinib), LOXO-292, an oral proto-oncogene receptor tyrosine kinase rearranged during transfection (RET) inhibitor, LOXO-305, an oral Bruton's tyrosine kinase (BTK) inhibitor, and LOXO-195, a follow-on TRK inhibitor. In March 2019, the company completed the corporate spin-off of Elanco. In August 2019, Elanco acquired the Bayer animal health business for $7.6 billion. In January 2020, the company announced its acquisition of Dermira for $1.1 billion, gaining control of lebrikizumab, glycopyrronium cloth used in the treatment of hyperhidrosis, and other assets.
=== Phase 1 === AH-001 – topical – alopecia – ubiquitin-protein ligase expression stimulant AMP-303 – intradermal – alopecia – undefined mechanism of action (polysaccharide) CKD-843 – oral, injection – alopecia – undefined mechanism of action CKR-051 – transdermal – alopecia – CXXC5 protein inhibitor, Wnt signalling pathway stimulant DR-01 – parenteral – alopecia areata – antibody-dependent cell cytotoxicity, T lymphocyte stimulant ET-02 (RS-5441) – topical – alopecia, hair disorders – undefined mechanism of action (targets and restores hair follicle stem cells) FOL-100 – topical – alopecia – undefined mechanism of action OLX-72021 – intradermal injection – alopecia – RNA interference QY-201 – oral – alopecia areata – Janus kinase 1 inhibitor, TYK2 kinase inhibitor SCO-240 – oral – alopecia – somatostatin receptor 5 modulator Squaric acid dibutyl ester (SQX-770) – topical – alopecia areata – immunomodulator VDAA – topical – alopecia areata – undefined mechanism of action
Sources: en.wikipedia.org
Diclofenac, sold under the brand name Voltaren among others, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammatory diseases such as gout. It can be taken orally (swallowed by mouth), inserted rectally as a suppository, injected intramuscularly, injected intravenously, applied to the skin topically, or through eye drops. Improvements in pain last up to eight hours. It is also available as the fixed-dose combination diclofenac/misoprostol (Arthrotec) to help protect the stomach; however, proton pump inhibitors such as omeprazole are typically first-line since they are at least as effective as misoprostol, but with better tolerability. Common side effects include abdominal pain, gastrointestinal bleeding, nausea, dizziness, headache, and swelling. Serious side effects may include heart disease, stroke, kidney problems, and stomach ulceration. Use is not recommended in the third trimester of pregnancy. It is likely safe during breastfeeding. Diclofenac is believed to work by decreasing the production of prostaglandins, like other drugs in this class. In 2023, it was the 73rd most commonly prescribed medication in the United States, with more than 9 million prescriptions. It is available as its acid or in two salts, as either diclofenac sodium or potassium.
=== Flavin-dependent ene-reductases === Flavin-dependent ERs perform their reactions using the cofactor flavin mononucleotide (FMN) that is non-covalently bonded to the enzyme and their catalytic mechanism is now well understood. In the natural cycle, the cofactor (FMN) is first reduced by NAD(P)H, then the reduced FMNH2 reduces the substrate by Michael-type hydride transfer to the β-carbon atom. In the end the protonation of the resulting anion occurs from the opposite face of the (C=C) bond through a tyrosine moiety or solvent. The overall reaction is an anti-trans-hydrogenation. This catalytic mechanism can also be regenerated from the natural nicotinamide cofactor with a substrate-coupled regeneration or the use of synthetic reductants and electrochemical or photochemical regeneration. The most predominant family of flavin-dependent ERs is the Old Yellow Enzyme (OYE) family of oxidoreductases (EC 1.6.99.1).The first OYE was discovered in baker's yeast (Saccharomyces cerevisiae) in 1933, and its name derives from the color it assumes when concentrated, which is due to the flavin cofactor. They catalyze the reduction of α,β-unsaturated compounds, with a high specificity for activating groups containing aldehydes, ketones, or nitro groups. Conversely, carboxylic acids and their derivatives such as esters and nitriles, are less activated and are considered as "borderline substrates".
Security forces (army, police and others) re-entered the area, only to join with the protesters. By 10:00, as the radio broadcast was announcing the introduction of martial law and a ban on groups larger than five persons, hundreds of thousands of people were gathering for the first time, spontaneously, in central Bucharest (the previous day's crowd had come together at Ceaușescu's orders). Ceaușescu attempted to address the crowd from the balcony of the Central Committee of the Communist Party building, but his attempt was met with a wave of disapproval and anger. Helicopters spread manifestos (which did not reach the crowd, due to unfavourable winds) instructing people not to fall victim to the latest "diversion attempts," but to go home instead and enjoy the Christmas feast. This order, which drew unfavourable comparisons to Marie Antoinette's haughty (but apocryphal) "Let them eat cake", further infuriated the people who did read the manifestos; many at that time had trouble procuring basic foodstuffs such as cooking oil.
At first glance, this result would seem to contradict the assertion that states choose alliance partners in order to balance against the strongest. Focusing solely on aggregate power would lead us to expect more states to ally with the Soviet Union, in order to prevent the United States from using its superior overall resources in harmful ways. Judging from the preponderance of aggregate power favoring the West, many states appear to have 'bandwagoned' rather than balanced by aligning with the United States. This is even more striking when one remembers that the United States was overwhelmingly the world's most powerful country in the immediate postwar period, yet was able to bring most of the other industrial powers into alignment with rather than against it. In 1986, still not envisaging the end of the Cold War in sight, Zbigniew Brzezinski emphasized the historical uniqueness of the current period regarding the preponderance of power: "[N]ever before would the eclipse of one of the major rival powers have given to the other effective global preponderance." Shortly after one of the rival superpowers eclipsed, the Pentagon Regional Defense Strategy (1992) formulized: "It is not in our interest … to return to earlier periods in which multiple military powers balanced one against another in what passed for security structures, while regional or even global peace hang in the balance." In the first post-Cold War year, Leffler advocated for the United States to continue its strategy of "preponderance of power".
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.